^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hematological Malignancies
    Drug:SAR443579 (NK cell stimulant, CD123 inhibitor, CD16 agonist, Natural cytotoxicity triggering receptor 1 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Innate Pharma Press Release
    Title:

    SAR'579 / IPH6101 RECEIVES FDA FAST TRACK DESIGNATION IN THE US FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES

    Published date:
    06/08/2023
    Excerpt:
    Innate Pharma SA...is pleased to share Sanofi’s news that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SAR’579 / IPH6101 for the treatment of hematological malignancies.